A multivalent structure comprised of an anti-EGFR VHH and two anti-HER2 affibodies coupled with Adriamycin, a chemotherapeutic drug, showed high anti-tumor activity both in vitro and in vivo [131]. This evidence concerns the gene EGFR and neoplasm.